The efficacy of azacitidine has been proved in two large phase III trials in intermediate-2 or high-risk myelodysplastic patients. The CALGB (Cancer and Leukemia Group B) study showed significantly prolonged median time to progression to leukaemia and/or death, whereas AZA 001 trial showed a prolonged overall survival (OS) compared with conventional care regimens. [1] [2] [3] Recently, it has been reported that abnormal karyotype independently predicted lower response rates to azacitidine and that intermediate-and poor-risk cytogenetics independently predicted poorer OS. 4 Inversion of chromosome 3 (inv(3) (q21;q26)), with EVI-1 (ecotropic viral integration site 1) transcriptional activation, is relatively common in myeloid malignancies and was reported in acute myeloid leukaemia, chronic myeloid leukaemia in blast crisis and myelodysplastic syndromes (MDS). 5 Usually, a distinct phenotype is associated with this cytogenetic aberration, such as trilineage dysplasia, thrombocytosis, young age, possible association with monosomy 7 or other complex karyotype changes, and poor prognosis because of scarce response to conventional chemotherapy. 6 No data were reported on the sensibility of MDS patients with this cytogenetic alteration to azacitidine. We here describe two MDS patients with inv(3)(q21;q26) who achieved morphological and cytogenetic response with azacitidine.
Case 1
A 59-year-old man was diagnosed as having WHO RAEB-1 (refractory anaemia with excess blast-1) type MDS, in November 2009. Peripheral blood count showed haemoglobin (Hb)
Letters to the Editor 9 g/dl, white blood cell (WBC) 2 Â 10 9 /l (absolute neutrophil count (ANC) 1.3 Â 10 9 /l) and platelets 433 Â 10 9 /l. Morphological analysis of bone marrow revealed 6% of blast cells with severe trilineage dysplasia, in particular in megakaryocytic line. Cytogenetic analysis at conventional level showed the inv(3)(q21;q26) in all analysed metaphases, with evidence of EVI-1 expression at fluorescence in situ hybridisation (FISH) analysis in all 300 examined nuclei. Human leukocyte antigen (HLA) search did not reveal a compatible donor and a search for compatible mismatched donors was activated. The patient was started on azacitidine at the standard dose of 75 mg/m 2 with a 5 þ 2 þ 2 schedule (5 days on, 2 days off and 2 days on) in January 2010. The patient did not experience haematological or non-haematological toxicities during therapy. After three cycles of azacitidine, bone marrow morphological analysis showed 3% of blast cells, whereas FISH analysis detected EVI-1 aberrant signal in 38% of nuclei. The patient continued the same therapy and after the sixth cycle, bone marrow aspiration was repeated that showed the absence of blast cells and the evidence of inv(3) in 47% of examined nuclei. At the present time, the patient is still receiving azacitidine treatment, in very good clinical conditions. 9 /l with ANC 2.3 Â 10 9 /l) and platelets (292 Â 10 9 /l), whereas bone marrow examination showed the absence of blast cells and a complete cytogenetic response at FISH analysis. At the present time, the patient is still on azacitidine, waiting for a bone marrow transplant.
The recent results of AZA 001 trial clearly established the efficacy of azacitidine compared with different conventional care regimens.
2 After a median follow-up of 21 months, the primary end point was reached with a prolonged OS in the azacitidine arm (24.5 months) compared with combined conventional care arms (15 months), with an estimated 2-year OS of 50.8%. The impact of the drug was also analysed in the setting of intermediate-poor cytogenetic risk, demonstrating the advantage in terms of survival of azacitidine compared with intensive or low-dose chemotherapy (13 vs 4 months, respectively). 2, 3 To our knowledge, this is the first report of cytogenetic responses in MDS patients with inv(3) not treated with intensive chemotherapy. As suggested for patients with intermediate-poor risk karyotype, 3 azacitidine could also be effective in the setting of patients with cytogenetic aberrations involving chromosome 3 and should be used as a bridge to bone marrow transplant or as a first-line treatment in MDS patients who are not immediately suitable for allogeneic transplantation, independently from the International Prognostic Scoring System (IPSS) risk category.
